Movalis (Meloxicam)

Meloxicam works by inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for producing prostaglandins. Lower prostaglandin levels lead to decreased inflammation, pain, and fever, providing symptomatic relief in affected tissues.

The appropriate dose of Movalis is determined by the prescribing healthcare professional based on the individual’s condition, age, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for meloxicam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Movalis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a longer half‑life and a relatively higher selectivity for COX‑2, which may reduce the incidence of gastrointestinal side effects. However, individual response and safety profiles vary, so clinicians choose the most appropriate NSAID based on patient risk factors.

Movalis should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Movalis is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may help lessen gastrointestinal discomfort. Patients should swallow the tablet whole and not split or crush it unless instructed otherwise.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe skin reactions, and renal or hepatic impairment. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Movalis is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulceration, severe heart failure, and patients with significant renal or hepatic impairment. It should also be avoided in patients taking certain anticoagulants or other NSAIDs without medical supervision.